Kymera disclosed enrollment completion for the BROADEN2 Phase 2b trial ahead of schedule, enabling an accelerated topline readout by year-end 2026. The company intends to start KT-621 Phase 3 by mid-2027, underscoring strong interest in its protein degradation platform. The stock’s rise to new highs amid a broad market rally highlights near-term upside but elevated RSI suggests a potential pullback.
Kymera Therapeutics' stock surged 46% after positive Phase 1b trial results. KT-621 demonstrated significant reductions in skin and blood STAT6 levels. Asthma patients showed a median 56% reduction in airway inflammation. Upcoming trials expected to sustain investor interest and price momentum. Kymera on track for potential record closing high in stock price.
Kymera Therapeutics reported positive trial results for anti-inflammatory drug KT-621. Shares surged over 40% to an all-time high following the announcement. KT-621 significantly reduces inflammation in patients with eczema and asthma. Ongoing and upcoming Phase 2b trials are expected to yield critical results. Shares are up approximately 140% year-to-date, indicating strong investor confidence.
Kymera's KT-621 trial data show promise for dermatitis and asthma. Stock jumped 50%, prompting multiple analysts to upgrade their ratings. Analysts predict annual sales of $1.3-$2.3 billion from KT-621 by 2035. The drug exhibits a clean safety profile compared to placebo. Potential partnership opportunity with Regeneron due to Dupixent's revenue gap.
